Friday, 11th of November
Coffee & registration
Coffee
Witte Vos
Welcome
(chair: Julie Nonnekens)
Witte Vos
Morning session 1
(chair: Julie Nonnekens)
Witte Vos
- Zinc finger protein ZNF384 is an adaptor of Ku to DNA during classical non-homologous end-joining (1Leiden University Medical Center, Leiden, The Netherlands)
- Identification and preclinical validation of metabolic bottlenecks for radiosensitization in the context of SLC25A1 inhibition. (1Institute of Cell Biology (Cancer Research), University Hospital Essen, University of Duis-burg-Essen, 45122 Essen, Germany)
- Regional immunological effects of proton therapy on the brain (1Department of Radiation Oncology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands.; 2Department of Biomedical Sciences of Cells and Systems, Section of Molecular Cell Biology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands.)
Break
Witte Vos
Morning session 2
(chair: Przemek Krawczyk)
Witte Vos
- INTO-PROT consortium (1UMCG)
- THERADNET, a Marie Curie Innovative Training network for early-stage researchers (1Maastro)
- Preclinical evaluation of targeted radionuclide therapy combined with immune checkpoint inhibition (1Department of Medical Imaging: Nuclear Medicine, Radboudumc, Nijmegen, The Netherlands)
Sponsor session
MILabs and Tromp Medical
Witte Vos
MILabs was founded in 2006 by Prof. Freek Beekman as a molecular imaging spin-off from the University Medical Centre Utrecht, the Netherlands. Today, the company is one of the global leaders in molecular imaging with the development of high-performance preclinical micro-PET, micro-SPECT, micro-CT, and Optical Tomography systems as well as human high-resolution SPECT. These imaging systems have received many international awards from the physics and molecular imaging community. Currently, MILabs’ imaging devices support the research of many hundreds of satisfied users worldwide at universities, CRO’s and pharmaceutical companies.
Tromp Medical is the largest independent medical imaging sales and service organization of Western Europe. They sell, install and maintain various types of medical imaging equipment from leading, highly innovative manufacturers, including Canon Medical Systems, Carestream, Hologic and Ziehm Imaging, throughout the Benelux, Nordics, France and Spain.
Tromp Medical has long-standing relations with a large client base across Western Europe with an installed base of over 5.000 medical imaging systems. Customers include university hospitals, general hospitals, private clinics, research centers and screening programs.
Poster session
Witte Vos
- Overcoming radioresistance induced by cycling hypoxia in Ewing Sarcoma by targeting metabolic adaptation mechanisms (1Institute of Cell Biology (Cancer Research), University Hospital Essen, University of Duisburg-Essen, 45122 Essen, Germany; 4German Cancer Consortium, partner site Essen, Essen, Germany)
- Airway stem cells from Chronic Obstructive Pulmonary Disease (COPD) patients preserve patient phenotypes and have increased radiation sensitivity. (1Department of Radiation Oncology (MAASTRO)/, GROW school for Oncology, Maastricht University, Maastricht, The Netherlands)
- Caffeic Acid Phenethyl Ester (CAPE), a natural radiosensitizer for lung adenocarcinomas (1The M-Lab, Department of Precision Medicine, GROW – School for Oncology and Reproduction, Maastricht University, Maastricht, the Netherlands)
- Defects in DNA Damage Response Machinery Pave the Avenue toward Radiation Quality-Specific Radiosensitivity of Cancer Cells (1West German Proton Therapy Center Essen (WPE), University of Duisburg-Essen, Essen, Germany.)
- Developing modulators of tumour hypoxia through inhibition of cellular oxygen consumption (1Oxford Institute for Radiation Oncology, Department of Oncology, University of Oxford, ORCRB, Oxford OX3 7DQ, UK)
- DNA-PK as a target for radiosensitization in high-risk Myc-Driven Medulloblastoma. (1Curie Institute, Paris, France.)
- Genetic and metabolic control of radiotherapy-induced breast cancer metastasis (1Pole of Pharmacology and Therapeutics, Institute of Experimental and Clinical Research (IREC), Universite catholique de Louvain (UCLouvain), Brussels, Belgium)
- Hyperthermia-mediated BRCA2 degradation enhances proton radiosensitivity of FaDu cells (1Department of Molecular Genetics, Erasmus MC Cancer Institute, Erasmus University Medical Center, Rotterdam, Netherlands; 2Oncode Institute, Erasmus University Medical Center, Rotterdam, Netherlands)
- Identification of a mitochondrial control of radioresistance in human breast cancer models (11Pole of Pharmacology and Therapeutics, Institute of Experimental and Clinical Research (IREC), Université catholique de Louvain (UCLouvain), Brussels, Belgium.)
- Impact of Ionizing Radiation on the Energy Metabolism of Normal and Tumor Cells in the Brain (1Laboratory for Applied Radiobiology, Dept. of Radiation Oncology, University Hospital Zurich, Zurich, Switzerland)
- Internalizing Radioimmunoconjugates to Target KRAS Cancer Cells for Simultaneous Radio-Ligand Therapy and Radiosensitization (1Oxford Institute for Radiation Oncology, Department of Oncology, University of Oxford, Oxford, UK)
- Interplay between DNA-PKcs and Rad54 in repair of X-ray induced DNA damage (1Department of Molecular Genetics, Erasmus MC Cancer Institute, Erasmus University Medical Center, 3015 GD Rotterdam, The Netherlands; 2Oncode Institute, Erasmus University Medical Center, 3015 GD Rotterdam, The Netherlands)
- Quantitative imaging of hypoxic CAIX+ areas in syngeneic mouse models (1Radiotherapy and OncoImmunology laboratory, Department of Radiation Oncology, Radboudumc, Nijmegen; 2Department of Medical Imaging, Radboudumc, Nijmegen)
- Targeting Survival Kinase DYRK1B: A novel approach to overcome radiotherapy-related treatment resistance (1Dept. Radiation Oncology, Laboratory for Applied Radiobiology, University Hospital Zurich)
- Targeting tumor associated macrophages improves the response of subcutaneous murine head and neck tumors (MOPC) to fractionated radiotherapy in vivo (1Department of Molecular Cell Biology, Institute of Cell Biology (Cancer Research), Medical Faculty, University of Duisburg-Essen, Essen, Germany)
Lunch
Witte Vos
NVRB members meeting
(chair: Haico van Attikum)
Witte Vos
Afternoon session 1
(chair: Haico van Attikum)
Witte Vos
- The radiobiological and dosimetric challenges to combining radiopharmaceutical and external beam radiation therapies (1Department of Oncology, University of Oxford, UK)
- Single-cell analysis reveals distinct responses of salivary gland stem cells to photon and proton irradiation (1Department of Biomedical Sciences of Cells Systems, University Medical Center Groningen, University of Groningen, Groningen – Netherlands; 2Department of Radiation Oncology, University Medical Center Groningen, University of Groningen, Groningen – Netherlands)
- AsiDNA protects the normal tissue against chemo- and radio-induced toxicity (1Institut Curie, PSL Research University, CNRS, INSERM, UMR 3347, F-91405, Orsay, France.; 2Université Paris Sud, Université Paris-Saclay, CNRS, UMR 3347, F-91405 Orsay, France)
Break
Witte Vos
Afternoon session 2
(chair: Marc Vooijs)
Witte Vos
- POLQ inhibitors as radiosensitizers - from concept to compounds (1University of Oxford, UK)
- Identification of signaling pathways driving radiation-induced adverse effects in the lung - Insight from systems analysis of radiation response networks (1Institute of Cell Biology (Cancer Research), University Hospital Essen, Essen, DE)
- Targeting serine/glycine metabolism to improve radiotherapy responses in Non-Small Cell Lung Cancer (1Maastricht University Medical Center+, Department of Radiation Oncology (MAASTRO), GROW School for Oncology and Reproduction, Maastricht, The Netherlands)
Drinks + announcements Klaas Breur travel awards
Witte Vos
